Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Sep 16 - Sep 21, 2021European Society of Medical Oncology (ESMO) Virtual Congress 2021
Sep 13, 2021 at 7:00 AM EDTH.C. Wainwright 23rd Annual Global Investment Conference
Jul 12, 2021 at 11:00 AM EDTH.C. WAINWRIGHT FIRESIDE CHAT WITH PHIO PHARMACEUTICALS